MYIA
ACAD icon

Mount Yale Investment Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

Mount Yale Investment Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-16
Closed -$345 – 681
2025
Q2 		$345 Buy
+16
New +$297 ﹤0.01% 1432
2018
Q2 		– Sell
-468
Closed -$11K – 947
2018
Q1 		$11K Buy
+468
New +$13K ﹤0.01% 835

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

Mount Yale Investment Advisors's ACAD Position: Q3 2025 in Review

Mount Yale Investment Advisors sold out of Acadia Pharmaceuticals (ACAD) in Q3 2025, closing a stake of 16 shares — an estimated $345 sold.

Mount Yale Investment Advisors first reported a position in ACAD in Q1 2018 and held it in 2 quarters. The position peaked at $11K in Q1 2018. 334 funds tracked by Wall St. Rank hold ACAD as of Q3 2025.

  • Mount Yale Investment Advisors reported no remaining Acadia Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Mount Yale Investment Advisors sold 16 Acadia Pharmaceuticals shares in Q3 2025, an estimated $345.
  • Mount Yale Investment Advisors first reported a position in Acadia Pharmaceuticals in Q1 2018 and held it in 2 quarters.
  • Mount Yale Investment Advisors's Acadia Pharmaceuticals position peaked at $11K in Q1 2018.
  • 334 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2025.

Based on Mount Yale Investment Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.